Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Sleep Initiation and Maintenance Disorders
Interventions
DRUG

KI1001

Prolonged release melatonin 2mg

DRUG

Placebo KI1001

Placebo KI1001 tablets

Trial Locations (10)

330-715

Dankook University Hospital, Cheonan

700-712

Keimyung University, Dongsan Medical Center, Daegu

200-722

Kangwon National University Hospital, Chuncheon

501-757

Chonnam National University Hospital, Gwangju

463-707

Seoul National University Bundang Hospital, Sungnam

442-723

St. Vincent Hospital, Suwon

130-709

St. Paul's Hospital, Seoul

134-727

Kyung Hee University Hospital at Gangdong, Seoul

138-736

Asan Medical Center, Seoul

143-729

Konkuk University Medical Center, Seoul

All Listed Sponsors
collaborator

Neurim Pharmaceuticals Ltd.

INDUSTRY

lead

Kuhnil Pharmaceutical Co., Ltd.

INDUSTRY

NCT01450228 - Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients | Biotech Hunter | Biotech Hunter